Guardant Health, Inc.
General ticker "GH" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $6.3B (TTM average)
Guardant Health, Inc. follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 2.8%: low 107.04$, high 113.21$
Factors to consider:
- Total employees count: 2021 as of 2024
- US accounted for 94.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Liquidity and credit risks, Labor/talent shortage/retention, Technological obsolescence
- Current price 204.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.77$, 44.75$]
- 2025-12-31 to 2026-12-31 estimated range: [14.89$, 36.80$]
Financial Metrics affecting the GH estimates:
- Negative: with PPE of -15.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.27 <= 0.04
- Positive: Industry inventory ratio change (median), % of -0.84 <= -0.18
- Positive: -14.19 < Investing cash flow per share per price, % of -6.83
- Negative: Shareholder equity ratio, % of -9.40 <= 19.35
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.07 <= 0.74
- Negative: negative Industry operating income (median)
Short-term GH quotes
Long-term GH plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $449.54MM | $563.95MM | $739.02MM |
| Operating Expenses | $993.92MM | $1,128.67MM | $1,182.61MM |
| Operating Income | $-544.38MM | $-564.73MM | $-443.59MM |
| Non-Operating Income | $-109.07MM | $85.96MM | $8.51MM |
| Interest Expense | $2.58MM | $2.58MM | $2.58MM |
| R&D Expense | $381.93MM | $388.72MM | $376.97MM |
| Income(Loss) | $-653.45MM | $-478.76MM | $-435.09MM |
| Taxes | $1.14MM | $0.69MM | $1.28MM |
| Profit(Loss)* | $-654.59MM | $-479.45MM | $-436.37MM |
| Stockholders Equity | $60.18MM | $158.68MM | $-139.65MM |
| Inventory | $51.60MM | $61.95MM | $71.08MM |
| Assets | $1,609.98MM | $1,786.42MM | $1,485.61MM |
| Operating Cash Flow | $-309.46MM | $-324.98MM | $-239.86MM |
| Capital expenditure | $77.46MM | $20.49MM | $35.09MM |
| Investing Cash Flow | $149.82MM | $840.25MM | $-261.31MM |
| Financing Cash Flow | $-189.09MM | $477.38MM | $-1.00MM |
| Earnings Per Share** | $-6.41 | $-4.28 | $-3.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.